RT Journal Article
SR Electronic
T1 Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 23
OP 29
DO 10.21873/anticanres.16784
VO 44
IS 1
A1 GOSHIMA, TSUBASA
A1 IEGUCHI, KATSUAKI
A1 ONISHI, NOBUYUKI
A1 SHIMIZU, TAKASHI
A1 TAKAYANAGI, DAISUKE
A1 WATANABE, MAKOTO
A1 FUJIMOTO, YUKI
A1 OHKUMA, RYOTARO
A1 SUZUKI, RISAKO
A1 TSURUI, TOSHIAKI
A1 MURA, EMIKO
A1 IRIGUCHI, NANA
A1 ISHIGURO, TOMOYUKI
A1 SHIMOKAWA, MASAHIRO
A1 HIRASAWA, YUYA
A1 KUBOTA, YUTARO
A1 ARIIZUMI, HIROTSUGU
A1 HORIIKE, ATSUSHI
A1 YOSHIMURA, KIYOSHI
A1 TSUJI, MAYUMI
A1 KIUCHI, YUJI
A1 KOBAYASHI, SHINICHI
A1 FUJISHIRO, JUN
A1 HOFFMAN, ROBERT M.
A1 TSUNODA, TAKUYA
A1 WADA, SATOSHI
YR 2024
UL http://ar.iiarjournals.org/content/44/1/23.abstract
AB Background/Aim: The response rate to immune checkpoint inhibitors (ICIs) is approximately 10%-30% and only in a few cancer types. In the present study, we determined whether non-classical monocytes (NCMs) could enhance ICI efficacy in colon cancer using a syngeneic mouse model. Materials and Methods: The MC38 C57BL/6 mouse colon cancer model was used. Cells collected from the bone marrow of C57BL/6 mice were cultured, and NCMs were fractionated by cell sorting and administered via the tail veins to the mice implanted with MC38 cells. The anti-mouse PD-L1 antibody was administered three times, and tumor volume and overall survival were observed. Results: More tumors were eradicated and more complete response occurred, after cotreatment with ICIs and NCMs than after treatment with ICIs alone. Moreover, no efficacy was observed when NCMs were administered alone. Conclusion: NCMs enhance ICI efficacy. The underlying mechanisms and clinical applications will be studied in the future.